MacroGenics Revenue and Competitors
Estimated Revenue & Valuation
- MacroGenics's estimated annual revenue is currently $116M per year.
- MacroGenics received $23.6M in venture funding in April 2017.
- MacroGenics's estimated revenue per employee is $302,846
- MacroGenics's total funding is $165.9M.
- MacroGenics's current valuation is $884.6M. (January 2022)
Employee Data
- MacroGenics has 383 Employees.
- MacroGenics grew their employee count by -6% last year.
MacroGenics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Executive Director Business Development | Reveal Email/Phone |
2 | VP | Reveal Email/Phone |
3 | VP | Reveal Email/Phone |
4 | General Counsel | Reveal Email/Phone |
5 | VP, Market Access & Reimbursement | Reveal Email/Phone |
6 | Head IT Quality and Compliance | Reveal Email/Phone |
7 | VP, Executive Director, Senior Director, Director Manufacturing | Reveal Email/Phone |
8 | VP, Facilities and Engineering | Reveal Email/Phone |
9 | VP, Contracts | Reveal Email/Phone |
10 | VP & Controller | Reveal Email/Phone |
MacroGenics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $15M | 204 | -6% | N/A | N/A |
What Is MacroGenics?
MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. MacroGenics most advanced program is margetuximab, an Fc-optimized monoclonal antibody that targets HER2, and is being investigated in the SOPHIA study, a Phase 3, randomized, multi-center clinical trial in patients with metastatic breast cancer.
keywords:Biotechnology,Healthcare,Pharmaceuticals
$165.9M
Total Funding
383
Number of Employees
$116M
Revenue (est)
-6%
Employee Growth %
$884.6M
Valuation
N/A
Accelerator
MacroGenics News
MacroGenics, Inc, a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its...
MacroGenics is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the...
MacroGenics, Inc, a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its...
ROCKVILLE, MD, Oct. 26, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial resu ...
MacroGenics Announces Clinical Results from Cohort A Part 1 of Phase 2/3 MAHOGANY Study of Margetuximab in Combination with Retifanlimab in Gastroesophageal Adenocarcinoma at ESMO 2021 •21 of 40 patients (53%) achieved confirmed responses by independent review, exceeding prespecified futility b ...
Other Companies in Rockville
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $80M | 388 | 24% | N/A |
#2 | $125.7M | 396 | 0% | N/A |
#3 | $93.1M | 410 | 1% | $638.2M |
#4 | $64.1M | 427 | 29% | N/A |
#5 | $136.9M | 447 | 75% | N/A |
MacroGenics Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2001-09-25 | $13.5M | A | Article | |
| 2002-06-07 | $12.6M | A+ | Article | |
| 2003-10-31 | $5.0M | Strategic Investmen | Genzyme | Article |
| 2004-10-18 | $30.5M | B | Alta Partners, TPG Ventures | Article |
| 2006-02-07 | $40.0M | Third | Article | |
| 2006-05-18 | $45.0M | Undisclosed | Multiple | Article |
| 2008-09-26 | $25.0M | D-2 | Nextech Venture | Article |
| 2014-02-12 | $Undisclosed | Undisclosed | BofA Merrill Lynch | Article |
| 2015-07-16 | $130.4M | Undisclosed | Morgan Stanley | Article |
| 2017-04-28 | $23.6M | Undisclosed | Article |